Global Epistaxis Market, by Indication (Anterior Epistaxis and Posterior Epistaxis), by Product Type (Vasoconstrictors, Anesthetics, Antibiotic Ointments, and Cauterizing Agents), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was estimated to be valued at US$ 145.9 million in 2019 and is projected to exhibit a CAGR of 5.4% over the forecast period (2019 - 2027).
An increasing number of patients are suffering from nasal tumors of benign and malignant types and is a major factor that is expected to drive the market growth during the forecast period. For instance, according to the American Cancer Society 2018, around 2,000 new cases related to nasal cavity and paranasal sinuses are registered every year in the U.S. The same article states that the sinuses that are highly responsible for epistaxis are much more prevalent in certain areas of the world that includes South Africa and Japan.
Furthermore, increasing emergency admission and inpatient admission regarding epistaxis is also contributing to growth of the market. For instance, according to the National Center for Biotechnology Information report, in 2018, 1 to 2 out of 200 visits to the emergency department and around 5% of patients admitted for inpatient care in the U.S. are due to epistaxis.
Moreover according to the same source, in 2015, a total of 19,841 patients (11,733 males and 8,108 females) received inpatient treatment for epistaxis in Germany.
Browse 35 Market Data Tables and 31Figures spread through 135 Pages and in-depth TOC on " Epistaxis Market, by Indication (Anterior Epistaxis and Posterior Epistaxis), by Product Type (Vasoconstrictors, Anesthetics, Antibiotic Ointments, and Cauterizing Agents), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027"
To know the latest trends and insights related to Epistaxis market, click the link below:
https://www.coherentmarketinsights.com/market-insight/epistaxis-market-771
An increasing cases of cardiovascular disorders, especially hypertensive diseases, which are highly susceptible to hemorrhage, is a major cause of epistaxis. According to the Medical Statistics of World Health Organization, in 2015 there were around 289,000 cases of hypertension recorded among pregnant women. According to the American Pregnancy Organization, the circulatory system expands during pregnancy so as to accommodate the baby. The expansion leads to increase in circulation of blood that may lead to problematic issues and frequent nosebleeds during pregnancy. Thus, rising number of pregnant women suffering from hypertensive diseases is expected to boost growth of the global epistaxis market.
Key Takeaways of the Epistaxis Market:
- The global epistaxis market is expected to witness a CAGR of 5.4% during the forecast period (2019–2027), owing to increasing number of patients suffering from nasal tumors of benign and malignant types
- Among indication, anterior epistaxis segment is expected to account for major revenue share in 2027, For instance, according to National Center For Biotechnology Information, the 90 % epistaxis are anterior originating from Kiesselbach’s plexus
- Major players operating in the global epistaxis market include Smith & Nephew, Medline Industries, Inc., Bristol-Myers Squibb Pharma Company, Ciron Drugs, and King Pharmaceuticals, Inc.
